The Renoprotective Effect of Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, in a Mouse Model of Renal Fibrosis

被引：0
|
作者：
Kim, Nayoung
Lee, In-Kyu
Park, Sung Don
Kim, Min-Ji
Kim, Jung-Guk
Choi, Yeon-Kyung
Park, Keun-Gyu
Kim, Mi-Jin
机构：
来源：
DIABETES | 2019年 / 68卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
10.2337/db19-511-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
511-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis
    Uchida, Takahiro
    Oda, Takashi
    Matsubara, Hidehito
    Watanabe, Atsushi
    Takechi, Hanako
    Oshima, Naoki
    Sakurai, Yutaka
    Kumagai, Hiroo
    RENAL FAILURE, 2017, 39 (01) : 340 - 349
  • [2] Renoprotective Effect of a Dipeptidyl Peptidase-4 Inhibitor on Aging Mice
    Ban, Tae H.
    Kim, Eun N.
    Kim, Min Y.
    Lim, Ji H.
    Lee, Jong H.
    Kim, Hyung D.
    Yoon, Hye E.
    Park, Cheol W.
    Choi, Bum S.
    AGING AND DISEASE, 2020, 11 (03): : 588 - 602
  • [3] Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
    Kim, Mi-Jin
    Kim, Na-young
    Jung, Yun-A
    Lee, Seunghyeong
    Jung, Gwon-Soo
    Kim, Jung-Guk
    Lee, In-Kyu
    Lee, Sungwoo
    Choi, Yeon-Kyung
    Park, Keun-Gyu
    DIABETES & METABOLISM JOURNAL, 2020, 44 (01) : 186 - 192
  • [4] The effect of the dipeptidyl peptidase-4 inhibitor linagliptin on proliferative retinopathy in a mouse model
    Dietrich, N.
    Schlotterer, A.
    Kern, L.
    Acunman, K.
    Klein, T.
    Hammes, H. -P.
    DIABETOLOGIA, 2016, 59 : S480 - S480
  • [5] The Effect of Dipeptidyl Peptidase-4 on Cardiac Fibrosis in Mouse Transverse Aortic Constriction Model
    Hirose, Masanori
    Takano, Hiroyuki
    Hasegawa, Hiroshi
    Kobara, Yuka
    Tadokoro, Hiroyuki
    Takemura, Genzou
    Kobayashi, Yoshio
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S205 - S205
  • [6] Effect of dipeptidyl peptidase-4 inhibitor on emphysema model in mice
    Joo, H.
    Kim, J. W.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [7] Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
    Bergman, Arthur J.
    Cote, Josee
    Yi, Bingming
    Marbury, Thomas
    Swan, Suzanne K.
    Smith, William
    Gottesdiener, Keith
    Wagner, John
    Herman, Gary A.
    DIABETES CARE, 2007, 30 (07) : 1862 - 1864
  • [8] Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin
    Graefe-Mody, U.
    Friedrich, C.
    Port, A.
    Ring, A.
    Retlich, S.
    Heise, T.
    Halabi, A.
    Woerle, H. -J.
    DIABETES OBESITY & METABOLISM, 2011, 13 (10): : 939 - 946
  • [9] Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229)
    Oh, Jaeseong
    Kim, Andrew HyoungJin
    Lee, SeungHwan
    Cho, Hyunjeong
    Kim, Yon Su
    Bahng, Mi Young
    Yoon, Seo Hyun
    Cho, Joo-Youn
    Jang, In-Jin
    Yu, Kyung-Sang
    DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 294 - 298
  • [10] Renoprotective Effect of Sitagliptin (Dipeptidyl Peptidase-4 Inhibitor) aganist Cisplatin Induced Nephrotoxicity in Mice
    Shalaby, Amany
    Malek, Hala Abdel
    BRITISH JOURNAL OF PHARMACEUTICAL RESEARCH, 2014, 4 (09): : 1116 - 1129
12345